the development of cancer immunotherapies would not
have been possible without basic research in immunology
and without the new technologies that exist today. Likewise,
drugs that were originally developed for cancer patients
have led to treatments for macular degeneration, hepatitis,
psoriasis, and other diseases.

To capitalize on the full breadth of our research enterprise,
both trainees and established investigators should be
encouraged and have opportunities to engage with and
learn from researchers across ;elds, including mathematics;
engineering; and the physical, chemical, and social sciences.